Venture capital firm profile
Sandalphon Capital
Chicago-based venture firm financing US startups from pre-seed through Series A, focusing on business software and marketplaces that modernize established industries in underserved markets.

United States, with emphasis on Chicago, the Midwest and underserved markets; typically excludes the Bay Area.
Typical pre-seed$100–250K, seed$500K–1M, SeriesA$1–2M; larger LP co-investments possible, currency code unspecified. US focus, usually excludes BayArea. B2B SaaS/marketplaces; excludes crypto, biotech/pharma/devices and advanced materials.
Typical checks: pre-seed $100–250k, seed $500k–$1m, Series A $1–2m; larger amounts possible via LP co-investment. Currency code unspecified.
Crypto, life sciences, biotech, pharmaceuticals, medical devices and advanced materials.
These pages were saved for the profile. They have not been mapped to individual claims.
United States, with emphasis on Chicago, the Midwest and underserved markets; typically excludes the Bay Area.
Sources checked
Pre-seed, seed and Series A
Sources checked
Typical pre-seed$100–250K, seed$500K–1M, SeriesA$1–2M; larger LP co-investments possible, currency code unspecified. US focus, usually excludes BayArea. B2B SaaS/marketplaces; excludes crypto, biotech/pharma/devices and advanced materials.
Sandalphon Capital invests across the United States with a particular emphasis on Chicago, the Midwest and underserved markets. It finances pre-seed, seed and Series A businesses using software or marketplaces to change established industries. Its sector interests include healthcare IT, insurance, finance, property and government, while several scientific and digital-asset categories are excluded.
Editorial profile by MoneyMakers. Sources reviewed . Profile source.
Chicago, United States
Loading profile details…
Loading recent changes…
Sources checked
Specific supporting source not yet mapped.
Typical checks: pre-seed $100–250k, seed $500k–$1m, Series A $1–2m; larger amounts possible via LP co-investment. Currency code unspecified.
Sources checked
Crypto, life sciences, biotech, pharmaceuticals, medical devices and advanced materials.
Sources checked